Iovance Biotherapeutics Statistics
Share Statistics
Iovance Biotherapeutics has 333.93M
shares outstanding. The number of shares has increased by 17.17%
in one year.
Shares Outstanding | 333.93M |
Shares Change (YoY) | 17.17% |
Shares Change (QoQ) | 7.58% |
Owned by Institutions (%) | 79.63% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 101,116 |
FTD / Avg. Volume | 0.8% |
Short Selling Information
The latest short interest is 77.02M, so 23.06% of the outstanding
shares have been sold short.
Short Interest | 77.02M |
Short % of Shares Out | 23.06% |
Short % of Float | 25.26% |
Short Ratio (days to cover) | 3.03 |
Valuation Ratios
The PE ratio is -5.76 and the forward
PE ratio is -2.48.
Iovance Biotherapeutics's PEG ratio is
0.18.
PE Ratio | -5.76 |
Forward PE | -2.48 |
PS Ratio | 13.07 |
Forward PS | 0.5 |
PB Ratio | 3.02 |
P/FCF Ratio | -5.89 |
PEG Ratio | 0.18 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.74,
with a Debt / Equity ratio of 0.08.
Current Ratio | 3.74 |
Quick Ratio | 3.31 |
Debt / Equity | 0.08 |
Debt / EBITDA | -0.17 |
Debt / FCF | -0.16 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $195,787.59 |
Profits Per Employee | $-444,125.3 |
Employee Count | 838 |
Asset Turnover | 0.18 |
Inventory Turnover | 2.41 |
Taxes
Income Tax | -2.83M |
Effective Tax Rate | 0.75% |
Stock Price Statistics
The stock price has increased by -77.65% in the
last 52 weeks. The beta is 1.06, so Iovance Biotherapeutics's
price volatility has been higher than the market average.
Beta | 1.06 |
52-Week Price Change | -77.65% |
50-Day Moving Average | 2.79 |
200-Day Moving Average | 6.78 |
Relative Strength Index (RSI) | 36.31 |
Average Volume (20 Days) | 12,691,504 |
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M
and earned -372.18M
in profits. Earnings per share was -1.28.
Revenue | 164.07M |
Gross Profit | 40.08M |
Operating Income | -395.28M |
Net Income | -372.18M |
EBITDA | -351.67M |
EBIT | -395.28M |
Earnings Per Share (EPS) | -1.28 |
Full Income Statement Balance Sheet
The company has 115.69M in cash and 58.26M in
debt, giving a net cash position of 57.43M.
Cash & Cash Equivalents | 115.69M |
Total Debt | 58.26M |
Net Cash | 57.43M |
Retained Earnings | -2.38B |
Total Assets | 966.74M |
Working Capital | 389.96M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -352.98M
and capital expenditures -11.07M, giving a free cash flow of -364.05M.
Operating Cash Flow | -352.98M |
Capital Expenditures | -11.07M |
Free Cash Flow | -364.05M |
FCF Per Share | -1.26 |
Full Cash Flow Statement Margins
Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.
Gross Margin | 24.43% |
Operating Margin | -240.92% |
Pretax Margin | -228.56% |
Profit Margin | -226.84% |
EBITDA Margin | -214.34% |
EBIT Margin | -240.92% |
FCF Margin | -221.88% |